GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (ASX:RHY) » Definitions » 10-Year Sharpe Ratio

Rhythm Biosciences (ASX:RHY) 10-Year Sharpe Ratio : N/A (As of Jul. 23, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Biosciences 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2025-07-23), Rhythm Biosciences's 10-Year Sharpe Ratio is Not available.


Competitive Comparison of Rhythm Biosciences's 10-Year Sharpe Ratio

For the Diagnostics & Research subindustry, Rhythm Biosciences's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences's 10-Year Sharpe Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's 10-Year Sharpe Ratio falls into.


;
;

Rhythm Biosciences 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.


Rhythm Biosciences  (ASX:RHY) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Rhythm Biosciences 10-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's 10-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences Business Description

Traded in Other Exchanges
N/A
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.

Rhythm Biosciences Headlines

No Headlines